Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma.

Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma. Nature communications Till, J. E., McDaniel, L., Chang, C., Long, Q., Pfeiffer, S. M., Lyman, J. P., Padrón, L. J., Maurer, D. M., Yu, J. X., Spencer, C. N., Gherardini, P. F., Da Silva, D. M., LaVallee, T. M., Abbott, C., Chen, R. O., Boyle, S. M., Bhagwat, N., Cannas, S., Sagreiya, H., Li, W., Yee, S. S., Abdalla, A., Wang, Z., Yin, M., Ballinger, D., Wissel, P., Eads, J., Karasic, T., Schneider, C., O'Dwyer, P., Teitelbaum, U., Reiss, K. A., Rahma, O. E., Fisher, G. A., Ko, A. H., Wainberg, Z. A., Wolff, R. A., O'Reilly, E. M., O'Hara, M. H., Cabanski, C. R., Vonderheide, R. H., Carpenter, E. L. 2024; 15 (1): 5763

Abstract

While high circulating tumor DNA (ctDNA) levels are associated with poor survival for multiple cancers, variant-specific differences in the association of ctDNA levels and survival have not been examined. Here we investigate KRAS ctDNA (ctKRAS) variant-specific associations with overall and progression-free survival (OS/PFS) in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) for patients receiving chemoimmunotherapy ("PRINCE", NCT03214250), and an independent cohort receiving standard of care (SOC) chemotherapy. For PRINCE, higher baseline plasma levels are associated with worse OS for ctKRAS G12D (log-rank p?=?0.0010) but not G12V (p?=?0.7101), even with adjustment for clinical covariates. Early, on-therapy clearance of G12D (p?=?0.0002), but not G12V (p?=?0.4058), strongly associates with OS for PRINCE. Similar results are obtained for the SOC cohort, and for PFS in both cohorts. These results suggest ctKRAS G12D but not G12V as a promising prognostic biomarker for mPDAC and that G12D clearance could also serve as an early biomarker of response.

View details for DOI 10.1038/s41467-024-49915-5

View details for PubMedID 38982051

View details for PubMedCentralID 8034833